FR2757061B1 - Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire - Google Patents

Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire

Info

Publication number
FR2757061B1
FR2757061B1 FR9615687A FR9615687A FR2757061B1 FR 2757061 B1 FR2757061 B1 FR 2757061B1 FR 9615687 A FR9615687 A FR 9615687A FR 9615687 A FR9615687 A FR 9615687A FR 2757061 B1 FR2757061 B1 FR 2757061B1
Authority
FR
France
Prior art keywords
avian
vector
infectious laryngotracheitis
laryngotracheitis virus
living vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR9615687A
Other languages
English (en)
Other versions
FR2757061A1 (fr
Inventor
Jean Christophe Audonnet
Michel Joseph Marie Bublot
Eliane Louise Francois Laplace
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Animal Health France SAS
Original Assignee
Rhone Merieux SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Merieux SA filed Critical Rhone Merieux SA
Priority to FR9615687A priority Critical patent/FR2757061B1/fr
Priority to US08/790,517 priority patent/US6033670A/en
Priority to MA24897A priority patent/MA24422A1/fr
Priority to ZA9711247A priority patent/ZA9711247B/xx
Priority to ARP970105886A priority patent/AR010086A1/es
Priority to JP52739498A priority patent/JP2001510338A/ja
Priority to TNTNSN97207A priority patent/TNSN97207A1/fr
Priority to PCT/FR1997/002307 priority patent/WO1998027215A1/fr
Priority to EP97952066A priority patent/EP0948637A1/fr
Priority to AU55627/98A priority patent/AU734085B2/en
Priority to CO97073364A priority patent/CO4650231A1/es
Publication of FR2757061A1 publication Critical patent/FR2757061A1/fr
Application granted granted Critical
Publication of FR2757061B1 publication Critical patent/FR2757061B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
FR9615687A 1996-12-16 1996-12-16 Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire Expired - Lifetime FR2757061B1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
FR9615687A FR2757061B1 (fr) 1996-12-16 1996-12-16 Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
US08/790,517 US6033670A (en) 1996-12-16 1997-01-29 Recombinant live avian vaccine, using as vector the avian infectious laryngotracheitis virus
MA24897A MA24422A1 (fr) 1996-12-16 1997-12-10 Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotrachaite infectieuse aviaire.
ARP970105886A AR010086A1 (es) 1996-12-16 1997-12-15 Vacuna recombinante aviaria que comprende como vector un virus iltv que comprende y expresa al menos una secuencia nucleotidicaheterologa
JP52739498A JP2001510338A (ja) 1996-12-16 1997-12-15 ベクターとして鳥類の感染性喉頭気管炎ウイルスを用いた鳥類用組換え生ワクチン
TNTNSN97207A TNSN97207A1 (fr) 1996-12-16 1997-12-15 Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
ZA9711247A ZA9711247B (en) 1996-12-16 1997-12-15 Recombinant live avian vaccine using as vector the avian infectious laryngotracheitis virus
PCT/FR1997/002307 WO1998027215A1 (fr) 1996-12-16 1997-12-15 Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
EP97952066A EP0948637A1 (fr) 1996-12-16 1997-12-15 Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
AU55627/98A AU734085B2 (en) 1996-12-16 1997-12-15 Recombinant live avian vaccine, using as vector the avian infectious laryngotracheitis virus.
CO97073364A CO4650231A1 (es) 1996-12-16 1997-12-16 Vacuna viva recombinante aviaria que utiliza como vector el virus de laringotraqueitis infecciosa aviaria

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9615687A FR2757061B1 (fr) 1996-12-16 1996-12-16 Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire

Publications (2)

Publication Number Publication Date
FR2757061A1 FR2757061A1 (fr) 1998-06-19
FR2757061B1 true FR2757061B1 (fr) 1999-03-26

Family

ID=9498887

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9615687A Expired - Lifetime FR2757061B1 (fr) 1996-12-16 1996-12-16 Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire

Country Status (11)

Country Link
US (1) US6033670A (fr)
EP (1) EP0948637A1 (fr)
JP (1) JP2001510338A (fr)
AR (1) AR010086A1 (fr)
AU (1) AU734085B2 (fr)
CO (1) CO4650231A1 (fr)
FR (1) FR2757061B1 (fr)
MA (1) MA24422A1 (fr)
TN (1) TNSN97207A1 (fr)
WO (1) WO1998027215A1 (fr)
ZA (1) ZA9711247B (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07206705A (ja) * 1993-11-03 1995-08-08 American Cyanamid Co 生インオボ（ｉｎ ｏｖｏ）ワクチン
WO1999018215A1 (fr) 1997-10-03 1999-04-15 Nippon Zeon Co., Ltd. Recombinants de virus herpetique infectieux aviaire et vaccins recombinants prepares avec ces derniers
AR031405A1 (es) * 2000-11-21 2003-09-24 Wyeth Corp Metodos y vacunas para conferir proteccion in ovo contra la rinotraqueitis del pavo
CA2443266A1 (fr) * 2001-02-13 2002-08-22 University Of Florida Double complexe promoteur bidirectionnel a activite promotrice amelioree dans le cadre de l'expression transgenique dans les eucaryotes
EP1241177A1 (fr) * 2001-03-15 2002-09-18 Akzo Nobel N.V. Virus recombinant de la laryngotrachéite infectieuse et vaccin
US20030157641A1 (en) * 2001-11-16 2003-08-21 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
CA2467363A1 (fr) 2001-11-16 2003-06-12 Idec Pharmaceuticals Corporation Expression polycistronique d'anticorps
US20040241723A1 (en) * 2002-03-18 2004-12-02 Marquess Foley Leigh Shaw Systems and methods for improving protein and milk production of dairy herds
US7083912B2 (en) * 2002-05-31 2006-08-01 Penn State Research Foundation MAb-based Dot-ELISA method and assay kit for the detection of viruses
EP1606419A1 (fr) 2003-03-18 2005-12-21 Quantum Genetics Ireland Limited Systemes et procedes pour accroitre la production de proteines et de lait chez des bovins laitiers
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
WO2005049794A2 (fr) 2003-11-13 2005-06-02 University Of Georgia Research Foundation, Inc. Procedes de caracterisation du virus de la bursite infectieuse
WO2005057272A2 (fr) * 2003-12-05 2005-06-23 Innfocus, Llc Modele ameliore de lentille oculaire
BRPI0507929A (pt) 2004-02-19 2007-07-17 Univ Alberta polimorfismos de promotor de leptina e seus usos
PT1881845E (pt) 2005-04-25 2010-05-31 Merial Ltd Vacinas de vírus nipah
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
JP2009515529A (ja) 2005-11-14 2009-04-16 メリアル リミテッド 腎不全のための遺伝子療法
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
CN103585643A (zh) 2009-04-03 2014-02-19 梅里亚有限公司 运载新城疫病毒的禽疫苗
US20130129780A1 (en) * 2010-08-02 2013-05-23 University Of Georgia Research Foundation, Inc. Modified infectious laryngotracheitis virus (iltv) and uses thereof
JP5913316B2 (ja) 2010-08-31 2016-04-27 メリアル リミテッド ニューカッスル病ウイルスをベクターとするヘルペスウイルスワクチン
WO2012090073A2 (fr) 2010-12-30 2012-07-05 The Netherlands Cancer Institute Procédés et compositions pour prédire la sensibilité à la chimiothérapie
US20140287931A1 (en) 2011-04-04 2014-09-25 Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis Methods and compositions for predicting resistance to anticancer treatment
WO2012138783A2 (fr) 2011-04-04 2012-10-11 Netherlands Cancer Institute Procédés et compositions pour prédire une résistance à un traitement anti-cancéreux
WO2012145577A1 (fr) 2011-04-20 2012-10-26 Merial Limited Vaccin antirabique avec adjuvant à profil de viscosité amélioré
AP2013007180A0 (en) 2011-04-25 2013-10-31 Advanced Bioscience Lab Inc Truncated HIV envelope proteins (ENV), methods andcompositions related thereto
US9669085B2 (en) 2011-06-01 2017-06-06 Merial Inc. Needle-free administration of PRRSV vaccines
DK2741740T3 (en) 2011-08-12 2017-06-06 Merial Inc VACUUM-SUPPORTED CONSERVATION OF BIOLOGICAL PRODUCTS, IN PARTICULAR OF VACCINES
WO2013057235A1 (fr) 2011-10-21 2013-04-25 Intervet International B.V. Vecteur mdv non pathogène recombinant conférant une immunité multivalente
AR088401A1 (es) 2011-10-21 2014-05-28 Intervet Int Bv Constructos del virus recombinante de la enfermedad de marek no patogenicos que codifican el virus de laringotraqueitis infecciosa y antigenos del virus de la enfermedad de newcastle
WO2013093629A2 (fr) 2011-12-20 2013-06-27 Netherlands Cancer Institute Vaccins modulaires, procédés et compositions qui y sont liés
WO2013138776A1 (fr) 2012-03-16 2013-09-19 Merial Limited Nouveaux procédés pour fournir une immunité de protection à long terme contre la rage chez des animaux, basés sur l'administration d'un flavivirus défectueux en termes de réplication, exprimant la rage g
US10709341B2 (en) 2012-11-21 2020-07-14 St. Jude Medical Luxembourg Holdings II S.a.r.l. Devices, systems, and methods for pulmonary arterial hypertension (PAH) assessment and treatment
US9556419B2 (en) 2013-03-12 2017-01-31 Merial Inc. Reverse genetics Schmallenberg virus vaccine compositions, and methods of use thereof
US9198908B2 (en) 2013-03-15 2015-12-01 St. Jude Medical Luxembourg Holdings Ii S.A.R.L. (“Sjm Lux Ii”) Methods for the treatment of cardiovascular conditions
EP3215188A1 (fr) 2014-11-03 2017-09-13 Merial, Inc. Procédés d'utilisation de formulations de vaccin par micro-aiguilles pour éliciter une immunité de protection contre le virus de la rage chez les animaux
EP3889166A1 (fr) 2015-06-23 2021-10-06 Boehringer Ingelheim Animal Health USA Inc. Vecteurs viraux recombinés contenant une protéine mineure de prrsv et leurs procédés de préparation et d'utilisation
RU2721575C2 (ru) 2015-06-30 2020-05-20 Сева Сантэ Анималь Вирус утиного энтерита и его применение
EP3263129A1 (fr) 2016-06-29 2018-01-03 Ceva Sante Animale Entérite virale du canard et son utilisation
CN113652406B (zh) * 2021-09-01 2023-05-02 青岛易邦生物工程有限公司 一种鸡传染性喉气管炎重组病毒株及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0353851B1 (fr) * 1988-06-24 1994-01-19 Btg International Limited Régions non essentielles du virus du fowlpox
EP0748631B1 (fr) * 1988-09-13 2006-02-08 Mérial Vaccins virales
WO1992003554A1 (fr) * 1990-08-24 1992-03-05 Arthur Webster Pty. Ltd. Vaccin contre le virus de la laryngotracheite infectieuse
FR2666589B1 (fr) * 1990-09-07 1994-08-05 Rhone Merieux Nouveaux virus herpes recombinants, vaccin a base de ces recombinants, leur procede de preparation, genes, vecteurs et plasmides utilises dans ce procede.
JPH09505726A (ja) * 1993-09-24 1997-06-10 シントロ・コーポレーション 組換え感染性喉頭気管炎ウイルス及びそれらの使用
AU2946395A (en) * 1994-06-30 1996-01-25 Board of Regents of the University of Illinois, The Recombinant infectious laryngotracheitis virus and vaccine
FR2722208B1 (fr) * 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
FR2728794B1 (fr) * 1994-12-30 1997-03-21 Rhone Merieux Vaccin recombinant aviaire a base de virus herpes aviaire, notamment contre la maladie de gumboro
FR2728795B1 (fr) * 1994-12-30 1997-03-21 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur un virus herpes aviaire
AU4489896A (en) * 1994-12-30 1996-07-24 Rhone Merieux Avian recombinant live vaccine
WO1996029396A1 (fr) * 1995-03-23 1996-09-26 Syntro Corporation Virus de la laryngotracheite infectieuse recombine et ses utilisations

Also Published As

Publication number Publication date
AU5562798A (en) 1998-07-15
AR010086A1 (es) 2000-05-17
FR2757061A1 (fr) 1998-06-19
ZA9711247B (en) 1999-06-17
CO4650231A1 (es) 1998-09-03
WO1998027215A1 (fr) 1998-06-25
TNSN97207A1 (fr) 2005-03-15
MA24422A1 (fr) 1998-07-01
US6033670A (en) 2000-03-07
JP2001510338A (ja) 2001-07-31
AU734085B2 (en) 2001-05-31
EP0948637A1 (fr) 1999-10-13

Similar Documents

Publication Publication Date Title
FR2757061B1 (fr) Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
FR2758986B1 (fr) Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
FR2750866B1 (fr) Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
FR2728795B1 (fr) Vaccin vivant recombinant aviaire, utilisant comme vecteur un virus herpes aviaire
LU91327I2 (fr) Vaccin papillomavirus humain Ätypes 56,11,16,18Ü(recombinant, adsorbé)
DE60040727D1 (de) Menschliche papillomavirus impfstoff-formulierungen
ZA964694B (en) Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection.
DE69730839D1 (de) Hühner polynukleotide impfstoff-formulierung
DE69800383T2 (de) Influenza Vaccine
ID30459A (id) Peptida-peptida makrosiklik yang aktif melawan virus hepatitis c
DK1210113T3 (da) Kombinerede vaccinepræparater
IL150961A0 (en) Human immunodeficiency virus vaccine
DK1058558T3 (da) Rekombinante og adjuverede vacciner mod influenzavirus og herpesvirus
EP0728842A3 (fr) Vaccin vivant recombinant aviaire à base de virus herpès aviaire, notamment contre la maladie de gumboro
EP0597016A4 (en) Infectious bursal disease virus recombinant poxvirus vaccine.
BR9712067A (pt) Pept¡dios imunog-nicos de v¡rus da doen-a de febre aftosa
ATE392903T1 (de) Impfstoff gegen pferdeherpesvirus
HUP0202770A3 (en) Human papilloma virus vaccine
DK1248650T3 (da) Forbedrede DNA-vacciner til bovint herpesvirus 1
DE60042130D1 (de) Neue antigene hev-peptide und methoden
IL143149A0 (en) Stable, attenuated rabies virus mutants and live vaccines thereof
AU5098700A (en) Dna vaccine for protecting an avian against infectious bursal disease virus
ATE333894T1 (de) Vakzine gegen infektiöse bursitis
HUP0002908A2 (en) Recombinant newcastle disease virus as embryo vaccine
GB9702990D0 (en) Virus vaccine

Legal Events

Date Code Title Description
CD Change of name or company name
CJ Change in legal form
PLFP Fee payment

Year of fee payment: 20